Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -870.38% is 15% below its 2-year average of -757.14%, near the high end of its 2-year range (-3057.57%–-8.35%).
21.57% above its 12-month average of -1109.81%.
Reported quarterly EBITDA margin; no daily interpolation. Q1 FY2014 (2014-02-28): -436.07%.
EBITDA MARGIN
-870.38%
EBITDA MARGIN AVG TTM
-1109.81%
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+21.57%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Relmada Therapeutics, Inc.
Market Cap
$348.23M
EBITDA Margin
-870.38%
TTM Avg
-1109.81%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$353.41M
EBITDA Margin
-153.75%
TTM Avg
-1289.79%
3Y Avg
-1338.35%
5Y Avg
-1135.96%
Market Cap
$357.76M
EBITDA Margin
-1371.56%
TTM Avg
-1336.69%
3Y Avg
-1827.03%
5Y Avg
-11314.18%
Market Cap
$357.08M
EBITDA Margin
-122.86%
TTM Avg
-149.66%
3Y Avg
-152.47%
5Y Avg
-125.05%
Market Cap
$357.26M
EBITDA Margin
18.25%
TTM Avg
18.77%
3Y Avg
18.63%
5Y Avg
20.30%
Market Cap
$357.88M
EBITDA Margin
-25837.05%
TTM Avg
-12960.93%
3Y Avg
-7440.06%
5Y Avg
-7440.06%
Market Cap
$358.14M
EBITDA Margin
-13.98%
TTM Avg
-3.54%
3Y Avg
-384.69%
5Y Avg
-2364.58%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Relmada Therapeutics, Inc. (RLMD) | $348.23M | -870.38% | -1109.81% | N/A | N/A |
| Turn Therapeutics Inc. (TTRX)vs › | $352.39M | N/A | N/A | N/A | N/A |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $353.41M | -153.75% | -1289.79% | -1338.35% | -1135.96% |
| Ocugen, Inc. (OCGN)vs › | $357.76M | -1371.56% | -1336.69% | -1827.03% | -11314.18% |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $357.08M | -122.86% | -149.66% | -152.47% | -125.05% |
| Viemed Healthcare, Inc. (VMD)vs › | $357.26M | 18.25% | 18.77% | 18.63% | 20.30% |
| Embecta Corp. (EMBC)vs › | $357.32M | 35.21% | 27.25% | 28.55% | 34.67% |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $357.88M | -25837.05% | -12960.93% | -7440.06% | -7440.06% |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $358.14M | -13.98% | -3.54% | -384.69% | -2364.58% |
| Opus Genetics, Inc. (IRD)vs › | $366.25M | -271.53% | -418.08% | -211.46% | -940.00% |
Gross Margin
0.0%
EBITDA Margin
-870.4%
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2014-02-28 | -436.07% |
| 2013-11-30 | -768.86% |
| 2013-05-31 | -3057.57% |
| 2013-02-28 | -176.73% |
| 2012-11-30 | -419.73% |
| 2012-08-31 | -569.57% |
| 2012-05-31 | -620.25% |
| 2012-02-29 | -8.35% |
